The Cancer Epidemiology, Prevention and Control (CEPC) Program seeks to reduce cancer incidence and mortality through research on environmental and genetic causes of cancer, early detection, risk reduction, and improved outcomes and quality of life. To accomplish this mission, our large, multi-disciplinary faculty conducts clinical and community-based studies in the general population, as well as in targeted and often underserved populations. The CEPC Program currently has 76 members from 14 departments and all three Consortium member institutions, representing multiple scientific disciplines, including epidemiology, genetics, sociology, psychology, internal medicine, medical oncology, communications, nutrition, biostatistics, and health economics. Thirty- nine CEPC faculty have primary appointments at FHCRC, 36 have primary appointments at UW, and one is based at Seattle Children's. CEPC faculty have been successful in obtaining independent funding to support their research: 93% have peer-reviewed cancer related research grants or contracts, are PI on a clinical trial, or are newly recruited investigators, resulting in a research portfolio (direct) totaling $25,984,344 in grants/contract funding, of which $21,616,050 is peer reviewed and $12,793,467 is from NCI. During the previous grant period, CEPC Program faculty published a total of 1655 papers, 25% of which were intra- programmatic, 32% were inter-programmatic, and 17% were inter-institutional. Important program resources include: the Puget Sound Surveillance Epidemiology and End Results (SEER) Cancer Registry, the Molecular Epidemiology and Biomarker Laboratories, large well-maintained cohorts such as the Women's Health Initiative (WHI), clinical trial groups including national coordinating centers, extensive data and biospecimen repositories, the Prevention Center Shared Resource, computational infrastructure and leadership, and nationally-recognized expertise with analysis and interpretation of genomic data. The CEPC Program continues to play an important role in the training of the next generation of cancer research/population scientists.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-44
Application #
9617723
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659
Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Amundsen, Susan K; Smith, Gerald R (2018) The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme. Nucleic Acids Res :
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Buckley, Sarah A; Percival, Mary-Elizabeth; Othus, Megan et al. (2018) A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leuk Lymphoma :1-7

Showing the most recent 10 out of 1267 publications